A new antibiotic is positive news—but it will take more to stay ahead of superbugs

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved gepotidacin (Blujepa) — the first new class of antibiotic for urinary tract infections (UTIs) in nearly 30 years. This is a major breakthrough for the millions of women suffering from recurrent UTIs, many of which no longer respond to existing antibiotics as over 90% of UTI bacteria are now resistant to at least one common drug. Gepotidacin works through a novel mechanism, blocking bacterial enzymes needed for replication, and has shown success even against resistant strains.

However, experts emphasize that one new antibiotic is not enough. Combating antimicrobial resistance (AMR) requires a multi-pronged approach: faster access to new medicines and diagnostics, real-world monitoring of antibiotic performance, and sustained scientific innovation in areas like microbiome and bacteriophage therapy. The MHRA’s Innovative Licensing and Access Pathway aims to speed the translation of promising tools to patients, while better use of real-world data—from clinics, hospitals, and wastewater—can track emerging resistance more effectively.

International collaboration is also crucial, as superbugs transcend borders. Partnerships such as the Global AMR Innovation Fund–MHRA initiative are helping innovators worldwide navigate clinical and regulatory barriers. The UK, with its strong infection research base, is encouraged to continue investing in antibiotics, vaccines, and diagnostics, supported by clear, adaptive regulation.

Ultimately, tackling AMR will require smarter antibiotic use, accelerated innovation, and stronger global cooperation—so that lifesaving treatments remain effective for future generations.